ILiAD Biotechnologies Selects Emmes Group for Global Phase III Trials of BPZE1 Pertussis Vaccine

25 June 2024 | Tuesday | News

Emmes Group’s VaxTrials and Veridix AI to Provide Critical Clinical Research and Technological Support for Multi-Continental Studies
Image Source : Public Domain

Image Source : Public Domain

  • Multiple Phase III studies are expected to be conducted across North America, Central and South America, UK and other global clinical sites
  • VaxTrials, part of Emmes Group, selected to provide comprehensive clinical research services
  • Veridix AI, part of Emmes Group, to provide Advantage eClinical and other platform capabilities critical to accelerate and improve study execution

ILiAD Biotechnologies, LLC, a late-stage biotech development company dedicated to the prevention of disease caused by Bordetella pertussis,  announced the selection of Emmes Group, a global contract research and technology organization, to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1.


ILiAD selected Emmes Group for their expertise in vaccine development, agility in managing complex clinical trials, strong local market presence, and their integrated technology capabilities. Emmes Groups’ VaxTrials unit has previously demonstrated proficiency and clinical trial excellence through their successful support of ILiAD’s Phase II IB-201P BPZE1 study.

Dr. Keith Rubin, CEO of ILiAD Biotechnologies, commented, “Selecting Emmes Group for our Phase III BPZE1 trials has been a carefully considered strategic decision to ensure the highest standards of clinical research. VaxTrials’ specialization in vaccines and Veridix AI’s advanced technological capabilities will be instrumental in executing our BPZE1 vaccine clinical development plan.”

"We are honored and pleased that ILiAD has selected Emmes Group as its partner to continue the clinical development of BPZE1. We look forward to working closely with ILiAD’s clinical development team on this promising new vaccine, which could significantly reduce the transmissibility and incidence of B. pertussis, particularly in vulnerable populations,” said Sastry Chilukuri, Chief Executive Officer of Emmes Group.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in